Q-omics provides the consensus-scored MAPK6P6 profile across patient tissues and cancer cell-line models. MAPK6P6 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MAPK6P6 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, MAPK6P6 RNA expression shows 6,010 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, KIRC, and STAD as cancer lineages where MAPK6P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAPK6P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAPK6P6 survival associations across molecular data types. MAPK6P6 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAPK6P6 RNA expression–survival associations across cancer types. High MAPK6P6 expression shows unfavorable associations in COAD, BLCA, UVM, ACC and PAAD, but favorable associations in GBM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify COAD as the clearest survival context for MAPK6P6 RNA expression.
This table summarizes MAPK6P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MAPK6P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAPK6P6 shows lower tumor expression in KIRC and higher tumor expression in THCA. The KIRC box plot shows higher MAPK6P6 RNA expression in normal versus tumor tissue (log2 FC = −0.022, t-test p = .039).
This table shows molecular features associated with MAPK6P6 in patient tissues and cancer cell lines. In patient samples, MAPK6P6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
